UDP-glucuronosyltransferase 2B15 (UGT2B15) Is the major enzyme responsible for sipoglitazar glucuronidation in humans: Retrospective identification of the ugt isoform by in vitro analysis and the effect of ugt2b15*2 mutation

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 6, 2013, Pages 475-484

  Nishihara, Mitsuhiro ^a   Hiura, Yuto ^a   Kawaguchi, Naohiro ^a   Takahashi, Junzo ^a   Asahi, Satoru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Glucuronidation; Peroxisome proliferator activated receptor (PPAR); Sipoglitazar; UGT2B15; polymorphism

Indexed keywords

ESTRADIOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; ISOENZYME; MESSENGER RNA; OXAZEPAM; SIPOGLITAZAR; UDP GLUCURONOSYLTRANSFERASE 2B15; UDP GLUCURONOSYLTRANSFERASE 2B4; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME KINETICS; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; IN VITRO STUDY; LIVER MICROSOME; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; OXAZEPAM; PROPIONATES; RETROSPECTIVE STUDIES; THIAZOLES;

EID: 84892984116     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-004     Document Type: Article

References (36)

1. Nishihara, M., Sudo, M., Kamiguchi, H., Kawaguchi, N., Maeshiba, Y., Kiyota, Y., Takahashi, J., Tagawa, Y., Kondo, T., et al.: Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro. Drug Metab. Pharmacokinet., 27: 223-231 (2012).
2. Nishihara, M., Sudou, M., Kawaguchi, N., Takahashi, J., Kiyota, Y., Kondo, T. and Asahi, S.: An unusual metabolic pathway of sipoglitazar, a novel anti-diabetic agent: Cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide. Drug Metab. Dispos., 40: 249-258 (2012).
3. Stringer, F., Ploeger, B., Jongh, J. de., Scott, G., Urquart, R., Karim, A. and Danhof, M.: Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist, sipoglitazar. J. Clin. Pharmacol., 53: 256-263 (2013).
4. Stringer, F., Scott, G., Valbuena, M., Kinley, J., Nishihara, M. and Urquhart, R.: The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. Eur. J. Clin. Pharmacol., 69: 423-430 (2013).
5. Mackenzie, P. I., Bock, K. W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., Miners, J. O., Owens, I. S. and Nebert, D. W.: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics, 15: 677-685 (2005).
6. Guillemette, C., Lévesque, E., Harvey, M., Bellemare, J. and Menard, V.: UGT genomic diversity: beyond gene duplication. Drug Metab. Rev., 42: 24-44 (2010).
7. Miners, J. O., Mackenzie, P. I. and Knights, K. M.: The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab. Rev., 42: 196-208 (2010).
8. Argikar, U. A., Iwuchukwu, O. F. and Nagar, S.: Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Expert Opin. Drug Metab. Toxicol., 4: 879-894 (2008).
9. Peters, W. H., te Morsche, R. H. and Roelofs, H. M.: Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J. Hepatol., 38: 3-8 (2003).
10. Massacesi, C., Terrazzino, S., Marcucci, F., Rocchi, M. B., Lippe, P., Bisonni, R., Lombardo, M., Pilone, A., Mattioli, R., et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer, 106: 1007-1016 (2006).
11. Nagar, S. and Blanchard, R. L.: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab. Rev., 38: 393-409 (2006).
12. Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii-Saab, T., Al-Rohaimi, A., von Moltke, L. L. and Greenblatt, D. J.: UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J. Pharmacol. Exp. Ther., 310: 656-665 (2004).
13. Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Jung, H. R., Lim, K. S., Jang, I. J. and Shin, S. G.: Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther., 77: 486-494 (2005).
14. Swanson, C., Mellström, D., Lorentzon, M., Vandenput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., et al.: The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and First American Title mass in men. J. Clin. Endocrinol. Metab., 92: 4878-4882 (2007).
15. Gsur, A., Preyer, M., Haidinger, G., Schatzl, G., Madersbacher, S., Marberger, M., Vutuc, C. and Micksche, M.: A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., 11: 497-498 (2002).
16. Lévesque, E., Beaulieu, M., Green, M. D., Tephly, T. R., Bélanger, A. and Hum, D. W.: Isolation and characterization of UGT2B15(Y85): a UDPglucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 7: 317-325 (1997).
17. Guillemette, C.: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J., 3: 136-158 (2003).
18. Lovdahl, M. J., Reher, K. E., Mann, H. J. and Remmel, R. P.: Determination of 4-methylumbelliferone and metabolites in Williams E medium and dog plasma by high performance liquid chromatography. J. Liq. Chromatogr., 17: 1795-1809 (1994).
19. Court, M. H.: Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol., 400: 104-116 (2005).
20. Court, M. H., Krishnaswamy, S., Hao, Q., Duan, S. X., Patten, C. J., Von Moltke, L. L. and Greenblatt, D. J.: Evaluation of 3A-azido-3Adeoxythymidine, morphine, and codeine as probe substrates for UDPglucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos., 31: 1125-1133 (2003).
21. Uchaipichat, V., Mackenzie, P. I., Guo, X. H., Gardner-Stephen, D., Galetin, A., Houston, J. B. and Miner, J. O.: Human UDP- glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 32: 413-423 (2004).
22. Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., Von Moltke, L. L. and Greenblatt, D. J.: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab. Dispos., 30: 1257-1265 (2002).
23. Bauman, J. N., Goosen, T. C., Tugnait, M., Peterkin, V., Hurst, S. I., Menning, L. C., Milad, M., Court, M. H. and Williams, J. A.: UDPglucuronosyltransferase 2B7 is the major enzyme responsible for Gemcabene glucuronidation in human liver microsomes. Drug Metab. Dispos., 33: 1349-1354 (2005).
24. Kaji, H. and Kume, T.: Identification of human UDP- glucuronosyltransferase isoform(s) responsible for the glucuronidation of 2-(4-chlorophenyl)- 5-(2-furyl)-4-oxazoleacetic acid (TA-1801A). Drug Metab. Pharmacokinet., 20: 212-218 (2005).
25. Hanioka, N., Tanabe, N., Jinno, H., Tanaka-Kagawa, T., Nagaoka, K., Naito, S., Koeda, A. and Narimatsu, S.: Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci., 87: 261-268 (2010).
26. Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von Moltke, L. L., Greenblatt, D. J. and Court, M. H.: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther., 313: 1340-1346 (2005).
27. Izukawa, T., Nakajima, M., Fujiwara, R., Yamanaka, H., Fukami, T., Takamiya, M., Aoki, Y., Ikushiro, S., Sakaki, T., et al.: Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab. Dispos., 37: 1759- 1768 (2009).
28. Ohno, S. and Nakajin, S.: Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos., 37: 32-40 (2009).
29. Court, M. H., Zhang, X., Ding, X., Yee, K. K., Hesse, L. M. and Finel, M.: Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica, 42: 266-277 (2012).
30. Lépine, J., Bernard, O., Plante, M., Têtu, B., Pelletier, G., Labrie, F., Bélanger, A. and Guillemette, C.: Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J. Clin. Endocrinol. Metab., 89: 5222-5232 (2004).
31. Soars, M. G., Fettes, M., O'Sullivan, A. C., Riley, R. J., Ethell, B. T. and Burchell, B.: Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily. Biochem. Pharmacol., 65: 1251-1259 (2003).
32. King, C. D., Green, M. D., Rios, G. R., Coffman, B. L., Owens, I. S., Bishop, W. P. and Tephly, T. R.: The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDPglucuronosyltransferase 1.1. Arch. Biochem. Biophys., 332: 92-100 (1996).
33. Dean, B., Chang, S., Stevens, J., Thomas, P. E. and King, C.: Isolation and characterization of a UDP-glucuronosyltransferase (UGT1A01) cloned from female rhesus monkey. Arch. Biochem. Biophys., 402: 289-295 (2002).
34. Kurkela, M., García-Horsman, J. A., Luukkanen, L., Mörsky, S., Taskinen, J., Baumann, M., Kostiainen, R., Hirvonen, J. and Finel, M.: Expression and characterization of recombinant human UDP- glucuronosyltransferases (UGTs). J. Biol. Chem., 278: 3536-3544 (2003).
35. Patel, M., Tang, B. K., Grant, D. M. and Kalow, W.: Interindividual variability in the glucuronidation of (S)-oxazepam contrasted with that of (R)-oxazepam. Pharmacogenetics, 5: 287-297 (1995).
36. Meech, R. and Mackenzie, P. I.: Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum. Arch. Biochem. Biophys., 356: 77-85 (1998).